Friday, February 2, 2018
From the Uh-Oh Department:
HCV Can Reactivate with Treatment of Non-hepatic Cancer. Hepatitis C virus (HCV) reactivation occurred in approximately 1 out of 5 patients treated for non-hepatic cancer, posing renewed risk for hepatic injury and possibly complicating the cancer treatment.
Compensation – New Update for 86-90 Late Claims. If you or a family member received a blood transfusion or blood products in Canada between January 1, 1986 and July 1, 1990 and contracted hepatitis C, you may be compensated up to $329,000 or more.
Child-Pugh B, C scores predict failure in liver cancer surveillance. This article is about what happens when people with cirrhosis are not part of a screening program for liver cancer.
Deaths from liver cancer nearly double since the 1990s, new figures reveal. Over the last two decades, deaths caused by liver cancer have increased by 80%, making it one of the fastest-growing causes of cancer deaths worldwide.
SVR for HCV with no advanced liver disease greatly reduces mortality risk. Patients with hepatitis C without advanced liver disease who achieved sustained virologic response with direct-acting antiviral therapy had significantly reduced all-cause mortality rates compared with both treated patients who did not achieve SVR and untreated patients.
Viral suppression protects against long-term liver damage caused by older HIV drugs. Most people living with HIV now have a normal life expectancy as a consequence of effective antiretroviral treatment, and viral suppression with modern therapies has been shown to have a beneficial effect on liver health.